Skip to content

RedHill Biopharma Ltd.

RDHL

CIK 0001553846 · Pharmaceutical Preparations · Nasdaq

← back to feed
Revenue (TTM)
$62.31M
+23.2% YoY FY Dec 2025
Net Income (TTM)
−$67.79M
−134.6% YoY FY Dec 2025
EPS Diluted (TTM)
$0.00
−100.0% YoY FY Dec 2025
Gross Margin
45.1%
FY Dec 2025
Operating Margin
-94.6%
FY Dec 2025
Net Margin
-108.8%
FY Dec 2025
Free Cash Flow (TTM)
—
FY Dec 2025
Cash
$2.87M
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
50.92B sh
FY Dec 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings